Overview

  • Product nameAnti-CD19 antibody [6D5] (PE/Cy5®)
    See all CD19 primary antibodies
  • Description
    Rat monoclonal [6D5] to CD19 (PE/Cy5®)
  • ConjugationPE/Cy5®. Ex: 496nm, Em: 670nm
  • SpecificityCD19 B-cell differentiation antigen
  • Tested applicationsSuitable for: Flow Cyt, IP, Functional Studiesmore details
  • Species reactivity
    Reacts with: Mouse
  • Immunogen

    Mouse CD19-expressing K562 human erythroleukemia cells

  • General notesThis product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5,268,486 and related patents. Cy and CyDye are trademarks of GE Healthcare Limited.

Properties

Applications

Our Abpromise guarantee covers the use of ab25508 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt
IP
Functional Studies
  • Application notesFlow Cyt: Use 0.2µg for 106 cells.
    IP: Use at an assay dependent dilution.
    In vivo and in vitro functional studies:Use at an assay dependent dilution.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionAssembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
    • Involvement in diseaseDefects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) [MIM:613493]; also called antibody deficiency due to CD19 defect. CVID3 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
    • Sequence similaritiesContains 2 Ig-like C2-type (immunoglobulin-like) domains.
    • Post-translational
      modifications
      Phosphorylated on serine and threonine upon DNA damage, probably by ATM or ATR. Phosphorylated on tyrosine following B-cell activation.
    • Cellular localizationMembrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • Antibody deficiency due to defect in CD19, included antibody
      • AW495831 antibody
      • B lymphocyte antigen CD19 antibody
      • B lymphocyte surface antigen B4 antibody
      • B-lymphocyte antigen CD19 antibody
      • B-lymphocyte surface antigen B4 antibody
      • B4 antibody
      • CD19 antibody
      • CD19 antigen antibody
      • CD19 molecule antibody
      • Cd19 protein antibody
      • CD19_HUMAN antibody
      • CVID3 antibody
      • Differentiation antigen CD19 antibody
      • Leu 12 antibody
      • Leu-12 antibody
      • Leu12 antibody
      • MGC109570 antibody
      • MGC12802 antibody
      • T-cell surface antigen Leu-12 antibody
      see all

    References for Anti-CD19 antibody [6D5] (PE/Cy5®) (ab25508)

    This product has been referenced in:

    See all 3 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab25508.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"